Literature DB >> 30858213

Introducing RpsA Point Mutations Δ438A and D123A into the Chromosome of Mycobacterium tuberculosis Confirms Their Role in Causing Resistance to Pyrazinamide.

Wanliang Shi1, Peng Cui1, Hongxia Niu2,3, Shuo Zhang1, Tone Tønjum4,5, Bingdong Zhu2,3, Ying Zhang6.   

Abstract

Pyrazinamide (PZA) is a unique frontline drug for shortening tuberculosis (TB) treatment, but its mechanisms of action are elusive. We previously found one PZA-resistant strain that harbors an alanine deletion at position 438 (Δ438A) in RpsA, a target of PZA associated with PZA resistance, but its role in causing PZA resistance has been inconclusive. Here, we introduced the RpsA Δ438A mutation along with the D123A mutation into the Mycobacterium tuberculosis chromosome and demonstrated that these RspA mutations are indeed responsible for PZA resistance.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosiszzm321990; RpsA; drug resistance mechanisms; pyrazinamide

Mesh:

Substances:

Year:  2019        PMID: 30858213      PMCID: PMC6535565          DOI: 10.1128/AAC.02681-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?

Authors:  Jim Werngren; Erik Alm; Mikael Mansjö
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China.

Authors:  Yaoju Tan; Zuqiong Hu; Tianyu Zhang; Xingshan Cai; Haobin Kuang; Yanwen Liu; Junyu Chen; Feng Yang; Ke Zhang; Shouyong Tan; Yanlin Zhao
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

3.  Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Ying Zhang; Sallie Permar; Zhonghe Sun
Journal:  J Med Microbiol       Date:  2002-01       Impact factor: 2.472

4.  The action of antituberculosis drugs in short-course chemotherapy.

Authors:  D A Mitchison
Journal:  Tubercle       Date:  1985-09

Review 5.  The curious characteristics of pyrazinamide: a review.

Authors:  Y Zhang; D Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2003-01       Impact factor: 2.373

6.  Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA.

Authors:  David C Alexander; Jennifer H Ma; Jennifer L Guthrie; Joanne Blair; Pam Chedore; Frances B Jamieson
Journal:  J Clin Microbiol       Date:  2012-08-15       Impact factor: 5.948

7.  Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.

Authors:  Catherine Vilchèze; Feng Wang; Masayoshi Arai; Manzour Hernando Hazbón; Roberto Colangeli; Laurent Kremer; Torin R Weisbrod; David Alland; James C Sacchettini; William R Jacobs
Journal:  Nat Med       Date:  2006-08-13       Impact factor: 53.440

8.  Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin.

Authors:  Hassan Safi; Brendan Sayers; Manzour H Hazbón; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

9.  Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA.

Authors:  Nicholas A Dillon; Nicholas D Peterson; Heather A Feaga; Kenneth C Keiler; Anthony D Baughn
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

10.  Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Shuo Zhang; Jiazhen Chen; Wanliang Shi; Peng Cui; Jia Zhang; Sanghyun Cho; Wenhong Zhang; Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2017-02-15       Impact factor: 7.163

View more
  6 in total

Review 1.  Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

Authors:  Pooja Gopal; Gerhard Grüber; Véronique Dartois; Thomas Dick
Journal:  Trends Pharmacol Sci       Date:  2019-11-06       Impact factor: 14.819

Review 2.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

3.  Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.

Authors:  Simone Mok; Emma Roycroft; Peter R Flanagan; Lorraine Montgomery; Emanuele Borroni; Thomas R Rogers; Margaret M Fitzgibbon
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

4.  Revised Interpretation of the Hain Lifescience GenoType MTBC To Differentiate Mycobacterium canettii and Members of the Mycobacterium tuberculosis Complex.

Authors:  Chloé Loiseau; Daniela Brites; Irmgard Moser; Francesc Coll; Christine Pourcel; Suelee Robbe-Austerman; Vincent Escuyer; Kimberlee A Musser; Sharon J Peacock; Silke Feuerriegel; Thomas A Kohl; Stefan Niemann; Sebastien Gagneux; Claudio U Köser
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.938

5.  Gibbs Free Energy Calculation of Mutation in PncA and RpsA Associated With Pyrazinamide Resistance.

Authors:  Muhammad Tahir Khan; Sajid Ali; Muhammad Tariq Zeb; Aman Chandra Kaushik; Shaukat Iqbal Malik; Dong-Qing Wei
Journal:  Front Mol Biosci       Date:  2020-04-09

6.  Galleria mellonella: An Infection Model for Screening Compounds Against the Mycobacterium tuberculosis Complex.

Authors:  Masanori Asai; Yanwen Li; Jasmeet Singh Khara; Brian D Robertson; Paul R Langford; Sandra M Newton
Journal:  Front Microbiol       Date:  2019-11-20       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.